- Home
- HCI vs COAG Comparison
HCI vs COAG Comparison
Compare HCI & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | COAG |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2008 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HCI | COAG |
|---|---|---|
| Price | $174.69 | $33.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $230.00 | N/A |
| AVG Volume (30 Days) | 104.2K | ★ 377.9K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 155.57 | N/A |
| EPS | ★ 11.05 | N/A |
| Revenue | ★ $900,946,000.00 | N/A |
| Revenue This Year | $11.44 | N/A |
| Revenue Next Year | $7.67 | N/A |
| P/E Ratio | $15.87 | ★ N/A |
| Revenue Growth | ★ 20.12 | N/A |
| 52 Week Low | $144.75 | $27.47 |
| 52 Week High | $210.50 | $55.42 |
Technical Indicators
Market Signals| Indicator | HCI | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 25.26 |
| Support Level | $172.50 | $29.54 |
| Resistance Level | $182.10 | $38.87 |
| Average True Range (ATR) | 4.01 | 3.02 |
| MACD | -1.50 | -0.71 |
| Stochastic Oscillator | 19.41 | 4.58 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.